Humacyte Reports Q2 Revenue Miss, Symvess Shows Progress in Hospital Access and Sales

Humacyte Inc. (HUMA) expands Symvess reach to 82 hospitals after FDA approval, with July sales surpassing half-year totals. Analysts project a potential 490.59% increase in stock value over the next year, rating the stock as "Outperform" due to its growth prospects.

Humacyte Inc. (HUMA), a commercial-stage biotechnology platform company, announced its second-quarter 2025 financial results and business updates, highlighting significant progress in the commercialization of its Symvess product. The company reported total revenues of $301,000 for the quarter, with $818,000 for the first six months of 2025, primarily from sales and collaborative research agreements [1].

One of the key highlights was the expansion of Symvess' reach to 82 civilian hospitals, following the approval of the product by 13 Value Analysis Committees (VACs). Additionally, the ECAT approval made Symvess available to approximately 190 Military Treatment Facilities and U.S. Department of Veterans Affairs hospitals [1].

The company also reported a substantial increase in sales during July, with revenues exceeding the total sales recorded during the first half of the year. This growth is attributed to the acceleration in VAC approvals and the first commercial sale to a U.S. military treatment facility in July [1].

Analysts project a potential 490.59% increase in stock value over the next year, rating the stock as "Outperform" due to its growth prospects. The company's financial results and market expansion indicate strong potential for future growth and revenue generation [1].

References:
[1] https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-second-quarter-2025-financial-results-and